Cellebrite DI (NASDAQ:CLBT) Given New $24.00 Price Target at JPMorgan Chase & Co.

Cellebrite DI (NASDAQ:CLBT) had its target price hoisted by JPMorgan Chase & Co. from $23.00 to $24.00 in a report released on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 25.36% from the company’s previous close.

Several other equities analysts have also recently weighed in on the company. Wall Street Zen cut Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Bank of America lifted their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, November 7th. Lake Street Capital boosted their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Needham & Company LLC upped their price objective on Cellebrite DI from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $24.00.

Cellebrite DI Trading Up 19.9%

Shares of NASDAQ:CLBT traded up $3.18 during mid-day trading on Thursday, reaching $19.15. The stock had a trading volume of 3,158,082 shares, compared to its average volume of 1,638,035. The firm has a 50 day simple moving average of $17.72 and a two-hundred day simple moving average of $16.69. Cellebrite DI has a twelve month low of $13.10 and a twelve month high of $26.30. The firm has a market cap of $4.58 billion, a PE ratio of -25.26, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Wednesday, November 12th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.05). The firm had revenue of $126.03 million during the quarter, compared to analyst estimates of $122.98 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company’s revenue for the quarter was up 17.9% on a year-over-year basis. During the same quarter last year, the business posted $0.14 earnings per share. Cellebrite DI has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts anticipate that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

Several hedge funds have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd bought a new position in shares of Cellebrite DI during the 2nd quarter worth approximately $657,000. Harbor Capital Advisors Inc. boosted its position in Cellebrite DI by 19.4% during the second quarter. Harbor Capital Advisors Inc. now owns 145,692 shares of the company’s stock worth $2,331,000 after purchasing an additional 23,638 shares during the period. Venturi Wealth Management LLC acquired a new position in shares of Cellebrite DI in the second quarter valued at $224,000. MQS Management LLC bought a new position in shares of Cellebrite DI in the second quarter valued at about $256,000. Finally, Nordea Investment Management AB lifted its stake in shares of Cellebrite DI by 2.1% during the 2nd quarter. Nordea Investment Management AB now owns 174,734 shares of the company’s stock worth $2,766,000 after buying an additional 3,644 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.